The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of larotrectinib in patients with non-primary central nervous system TRK fusion cancer: An updated analysis.
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Hutchison MediPharma; Junshi Pharmaceuticals; Keymed Biosience; MSD; QiLu Pharmaceutical
 
David Hong
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - crossbridge Bio; MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Amgen; Bayer; BeiGene; Bristol Myers Squibb Company; Janssen; Mirati Therapeutics; Sanofi and Genzyme US Companies
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Deciphera Pharmaceuticals Inc. (Inst); Genentech (Inst); Incyte (Inst); Merck Sharp & Dohme LLC (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; CLCC; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Cornelis van Tilburg
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Novartis; Roche
Travel, Accommodations, Expenses - Lilly
 
Daniel Orbach
Honoraria - Bayer Health (Inst); Bayer Health (Inst); EUSA Pharma (Inst); Merck; Novartis (Inst); Roche (Inst)
Consulting or Advisory Role - Bayer (Inst); Merck (Inst)
Research Funding - Bayer (Inst)
 
Daniel Tan
Honoraria - Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); DKSH (Inst); Genmab; Merck (Inst); Pfizer (Inst); Roche (Inst); Zymeworks
Research Funding - ACM Biolabs (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Jessica Lin
Honoraria - Curio Science; HMP Education; Medscape; OncLive; PeerView
Consulting or Advisory Role - Anheart Therapeutics; AstraZeneca; Bayer; Blueprint Medicines; Bristol Myers Squibb; CLaiM Therapeutics; Daiichi Sankyo/Astra Zeneca; Elevation Oncology; Ellipses Pharma; Genentech; Gilead Sciences; Hyku Biosciences; Janssen; Lilly; Merus; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Nuvation Bio; Pfizer; Regeneron; Roche/Genentech; Takeda; Turning Point Therapeutics; Yuhan
Research Funding - Bayer (Inst); Bristol Myers Squibb; Elevation Oncology (Inst); Linnaeus Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Sutro Biopharma; Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Merus; Pfizer; Takeda
 
Birgit Geoerger
Consulting or Advisory Role - AZD; Novartis; Roche/Genentech
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); Fortress Biotech; PathomIQ
Consulting or Advisory Role - AADi; Bayer; BPGBio; Cadila Pharmaceuticals (I); Daiichi Sankyo; Genome Insight; GI Innovations Inc.; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; MOMA Therapeutics; Mundipharma; Oxford BioTherapeutics; Seagan; SpringWorks Therapeutics; XY One Therapeutics
Research Funding - Adanate Inc. (Inst); ADC Therapeutics (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Day One Therapeutics (Inst); Deciphera (Inst); Elevation Oncology (Inst); Fog Pharmaceuticals (Inst); Genome & Company (Inst); Gilead Sciences (Inst); GV20 Therapeutics (Inst); Immunitas (Inst); Incyte (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Nuvectis Pharma Inc. (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Transcenta (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Bayer
 
Ulrik Lassen
Honoraria - Bayer; Novartis; Pfizer
Consulting or Advisory Role - Bayer; Pfizer
Research Funding - BMS (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Pfizer (Inst); Roche (Inst)
 
Raymond McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Domnita-Ileana Burcoveanu
Employment - Bayer
 
Nicoletta Brega
Employment - Bayer
 
Natascha Neu
Other Relationship - Bayer
 
Theodore Laetsch
Stock and Other Ownership Interests - Advanced Microbubbles
Consulting or Advisory Role - AI Therapeutics; Bayer; GlaxoSmithKline; ITM Oncologics; Jazz Pharmaceuticals
Research Funding - Adaptimmune (Inst); Advanced Accelerator Applications/Novartis (Inst); Bayer (Inst); BioAtla (Inst); Exelixis (Inst); ITM Oncologics (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Taiho Oncology (Inst); Turning Point Therapeutics (Inst)
 
Changsong Qi
Consulting or Advisory Role - AstraZeneca; CARsgen Therapeutics
Speakers' Bureau - CStone Pharmaceuticals; Jiangsu Hengrui; Zai Lab
 
Alexander Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva